A single center's experience of the extrapulmonary neuroendocrine carcinomas
Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare tumor type, and a standard therapy for EP-NEC has not yet been established. The purpose of this research was to explore the overall survival (OS) and therapeutic effects of platinum-etoposide combination therapy in EP-NEC. This retrospective...
Gespeichert in:
| Veröffentlicht in: | Northern Clinics of Istanbul 2022, Vol.9 (1), p.35-40 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 40 |
|---|---|
| container_issue | 1 |
| container_start_page | 35 |
| container_title | Northern Clinics of Istanbul |
| container_volume | 9 |
| creator | Celik, Emir Samanci, Nilay Sengul Derin, Sumeyra Bedir, Sahin Degerli, Ezgi Oruc, Kerem Oztas, Nihan Senturk Alkan, Gulin Senyigit, Abdulhalim Turna, Zeynep Hande |
| description | Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare tumor type, and a standard therapy for EP-NEC has not yet been established. The purpose of this research was to explore the overall survival (OS) and therapeutic effects of platinum-etoposide combination therapy in EP-NEC.
This retrospective study was conducted based on the medical records from January 2010 to March 2020. Eligible patients had been pathologically diagnosed with EP-NEC.
Forty-seven patients were included in the study. About 72.3% (n=34) of the patients were diagnosed with metastatic disease at the first diagnosis. The most common primary tumor site was the stomach. The median progression-free survival (PFS) of the patient group, who received the combination of platinum/etoposide, was 5.83 months (95% CI 4.46-7.20), whereas the median OS of the patients, who were found to have metastatic disease at the first diagnosis, was 13.6 months (95% CI 9.01-18.18). There was no difference in PFS and OS between patients with and without liver metastasis.
The outcome of advanced EP-NECs with platinum/etoposide chemotherapy remains poor. Obviously, there is a need for new, more effective treatment options. |
| doi_str_mv | 10.14744/nci.2021.47887 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8889205</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A789049144</galeid><sourcerecordid>A789049144</sourcerecordid><originalsourceid>FETCH-LOGICAL-g276t-4605659524bda52fe9e7f7fe7fcc0f6b6fb4476c63cde50e308bbe521cafe8883</originalsourceid><addsrcrecordid>eNptUU1r3DAQFaWhCWnOvQVDDu3FG1kaSfYlsCxtUljIJT0LWR5tFGxpI9kl-ffV0vQjpQhGw-i9N-8hQj40dNWAArgM1q8YZc0KVNuqN-SECS5rEIK_LX0DbQ0dZcfkLOcHSmmjgFHJ3pFjLjhQ3ogTsl1X2YfdiJXFMGP6mCt82mPyGCxW0VXzPZbJnMx-GacYTHquAi4pYhiiTT4UoknWhziZ_J4cOTNmPHu5T8m3L5_vNjf19vb662a9rXdMybkGSYUUnWDQD0Ywhx0qp1wp1lIne-l6ACWt5HZAQZHTtu9RsMYah23b8lNy9VN3v_QTDgfnyYx6n_xU_OlovH79Evy93sXvupA7RkUR-PQikOLjgnnWk88Wx9EEjEvWTALw4lBCgV78A32ISwolnua0E5zLYugPamdG1D64WPbag6heq7aj0DVw0Fr9B1XOgJO3MaDzZf6KcP530N8Jf_0f_wEoi53p</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3095336883</pqid></control><display><type>article</type><title>A single center's experience of the extrapulmonary neuroendocrine carcinomas</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Celik, Emir ; Samanci, Nilay Sengul ; Derin, Sumeyra ; Bedir, Sahin ; Degerli, Ezgi ; Oruc, Kerem ; Oztas, Nihan Senturk ; Alkan, Gulin ; Senyigit, Abdulhalim ; Turna, Zeynep Hande</creator><creatorcontrib>Celik, Emir ; Samanci, Nilay Sengul ; Derin, Sumeyra ; Bedir, Sahin ; Degerli, Ezgi ; Oruc, Kerem ; Oztas, Nihan Senturk ; Alkan, Gulin ; Senyigit, Abdulhalim ; Turna, Zeynep Hande</creatorcontrib><description>Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare tumor type, and a standard therapy for EP-NEC has not yet been established. The purpose of this research was to explore the overall survival (OS) and therapeutic effects of platinum-etoposide combination therapy in EP-NEC.
This retrospective study was conducted based on the medical records from January 2010 to March 2020. Eligible patients had been pathologically diagnosed with EP-NEC.
Forty-seven patients were included in the study. About 72.3% (n=34) of the patients were diagnosed with metastatic disease at the first diagnosis. The most common primary tumor site was the stomach. The median progression-free survival (PFS) of the patient group, who received the combination of platinum/etoposide, was 5.83 months (95% CI 4.46-7.20), whereas the median OS of the patients, who were found to have metastatic disease at the first diagnosis, was 13.6 months (95% CI 9.01-18.18). There was no difference in PFS and OS between patients with and without liver metastasis.
The outcome of advanced EP-NECs with platinum/etoposide chemotherapy remains poor. Obviously, there is a need for new, more effective treatment options.</description><identifier>ISSN: 2148-4902</identifier><identifier>ISSN: 2149-4902</identifier><identifier>EISSN: 2536-4553</identifier><identifier>DOI: 10.14744/nci.2021.47887</identifier><identifier>PMID: 35340315</identifier><language>eng</language><publisher>Turkey: KARE Publishing</publisher><subject>Cancer ; Care and treatment ; Chemotherapy ; Combination therapy ; Development and progression ; Etoposide ; Health aspects ; Liver ; Medical records ; Medical research ; Medicine, Experimental ; Metastasis ; Original - Medical Oncology ; Patients</subject><ispartof>Northern Clinics of Istanbul, 2022, Vol.9 (1), p.35-40</ispartof><rights>Copyright © by by Istanbul Provincial Directorate of Health - Available online at www.northclinist.com.</rights><rights>COPYRIGHT 2022 KARE Publishing</rights><rights>2022. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © by by Istanbul Provincial Directorate of Health - Available online at 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-0430-6421 ; 0000-0002-5797-0804 ; 0000-0002-5362-0284 ; 0000-0003-0558-9371 ; 0000-0003-4658-1552 ; 0000-0003-2394-3012 ; 0000-0001-8440-3082 ; 0000-0003-4966-3561 ; 0000-0002-4318-2129 ; 0000-0002-8664-5701</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889205/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889205/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35340315$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Celik, Emir</creatorcontrib><creatorcontrib>Samanci, Nilay Sengul</creatorcontrib><creatorcontrib>Derin, Sumeyra</creatorcontrib><creatorcontrib>Bedir, Sahin</creatorcontrib><creatorcontrib>Degerli, Ezgi</creatorcontrib><creatorcontrib>Oruc, Kerem</creatorcontrib><creatorcontrib>Oztas, Nihan Senturk</creatorcontrib><creatorcontrib>Alkan, Gulin</creatorcontrib><creatorcontrib>Senyigit, Abdulhalim</creatorcontrib><creatorcontrib>Turna, Zeynep Hande</creatorcontrib><title>A single center's experience of the extrapulmonary neuroendocrine carcinomas</title><title>Northern Clinics of Istanbul</title><addtitle>North Clin Istanb</addtitle><description>Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare tumor type, and a standard therapy for EP-NEC has not yet been established. The purpose of this research was to explore the overall survival (OS) and therapeutic effects of platinum-etoposide combination therapy in EP-NEC.
This retrospective study was conducted based on the medical records from January 2010 to March 2020. Eligible patients had been pathologically diagnosed with EP-NEC.
Forty-seven patients were included in the study. About 72.3% (n=34) of the patients were diagnosed with metastatic disease at the first diagnosis. The most common primary tumor site was the stomach. The median progression-free survival (PFS) of the patient group, who received the combination of platinum/etoposide, was 5.83 months (95% CI 4.46-7.20), whereas the median OS of the patients, who were found to have metastatic disease at the first diagnosis, was 13.6 months (95% CI 9.01-18.18). There was no difference in PFS and OS between patients with and without liver metastasis.
The outcome of advanced EP-NECs with platinum/etoposide chemotherapy remains poor. Obviously, there is a need for new, more effective treatment options.</description><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Combination therapy</subject><subject>Development and progression</subject><subject>Etoposide</subject><subject>Health aspects</subject><subject>Liver</subject><subject>Medical records</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Metastasis</subject><subject>Original - Medical Oncology</subject><subject>Patients</subject><issn>2148-4902</issn><issn>2149-4902</issn><issn>2536-4553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptUU1r3DAQFaWhCWnOvQVDDu3FG1kaSfYlsCxtUljIJT0LWR5tFGxpI9kl-ffV0vQjpQhGw-i9N-8hQj40dNWAArgM1q8YZc0KVNuqN-SECS5rEIK_LX0DbQ0dZcfkLOcHSmmjgFHJ3pFjLjhQ3ogTsl1X2YfdiJXFMGP6mCt82mPyGCxW0VXzPZbJnMx-GacYTHquAi4pYhiiTT4UoknWhziZ_J4cOTNmPHu5T8m3L5_vNjf19vb662a9rXdMybkGSYUUnWDQD0Ywhx0qp1wp1lIne-l6ACWt5HZAQZHTtu9RsMYah23b8lNy9VN3v_QTDgfnyYx6n_xU_OlovH79Evy93sXvupA7RkUR-PQikOLjgnnWk88Wx9EEjEvWTALw4lBCgV78A32ISwolnua0E5zLYugPamdG1D64WPbag6heq7aj0DVw0Fr9B1XOgJO3MaDzZf6KcP530N8Jf_0f_wEoi53p</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Celik, Emir</creator><creator>Samanci, Nilay Sengul</creator><creator>Derin, Sumeyra</creator><creator>Bedir, Sahin</creator><creator>Degerli, Ezgi</creator><creator>Oruc, Kerem</creator><creator>Oztas, Nihan Senturk</creator><creator>Alkan, Gulin</creator><creator>Senyigit, Abdulhalim</creator><creator>Turna, Zeynep Hande</creator><general>KARE Publishing</general><general>Kare Publishing</general><general>Health Directorate of Istanbul</general><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0430-6421</orcidid><orcidid>https://orcid.org/0000-0002-5797-0804</orcidid><orcidid>https://orcid.org/0000-0002-5362-0284</orcidid><orcidid>https://orcid.org/0000-0003-0558-9371</orcidid><orcidid>https://orcid.org/0000-0003-4658-1552</orcidid><orcidid>https://orcid.org/0000-0003-2394-3012</orcidid><orcidid>https://orcid.org/0000-0001-8440-3082</orcidid><orcidid>https://orcid.org/0000-0003-4966-3561</orcidid><orcidid>https://orcid.org/0000-0002-4318-2129</orcidid><orcidid>https://orcid.org/0000-0002-8664-5701</orcidid></search><sort><creationdate>2022</creationdate><title>A single center's experience of the extrapulmonary neuroendocrine carcinomas</title><author>Celik, Emir ; Samanci, Nilay Sengul ; Derin, Sumeyra ; Bedir, Sahin ; Degerli, Ezgi ; Oruc, Kerem ; Oztas, Nihan Senturk ; Alkan, Gulin ; Senyigit, Abdulhalim ; Turna, Zeynep Hande</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g276t-4605659524bda52fe9e7f7fe7fcc0f6b6fb4476c63cde50e308bbe521cafe8883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Combination therapy</topic><topic>Development and progression</topic><topic>Etoposide</topic><topic>Health aspects</topic><topic>Liver</topic><topic>Medical records</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Metastasis</topic><topic>Original - Medical Oncology</topic><topic>Patients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Celik, Emir</creatorcontrib><creatorcontrib>Samanci, Nilay Sengul</creatorcontrib><creatorcontrib>Derin, Sumeyra</creatorcontrib><creatorcontrib>Bedir, Sahin</creatorcontrib><creatorcontrib>Degerli, Ezgi</creatorcontrib><creatorcontrib>Oruc, Kerem</creatorcontrib><creatorcontrib>Oztas, Nihan Senturk</creatorcontrib><creatorcontrib>Alkan, Gulin</creatorcontrib><creatorcontrib>Senyigit, Abdulhalim</creatorcontrib><creatorcontrib>Turna, Zeynep Hande</creatorcontrib><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Northern Clinics of Istanbul</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Celik, Emir</au><au>Samanci, Nilay Sengul</au><au>Derin, Sumeyra</au><au>Bedir, Sahin</au><au>Degerli, Ezgi</au><au>Oruc, Kerem</au><au>Oztas, Nihan Senturk</au><au>Alkan, Gulin</au><au>Senyigit, Abdulhalim</au><au>Turna, Zeynep Hande</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A single center's experience of the extrapulmonary neuroendocrine carcinomas</atitle><jtitle>Northern Clinics of Istanbul</jtitle><addtitle>North Clin Istanb</addtitle><date>2022</date><risdate>2022</risdate><volume>9</volume><issue>1</issue><spage>35</spage><epage>40</epage><pages>35-40</pages><issn>2148-4902</issn><issn>2149-4902</issn><eissn>2536-4553</eissn><abstract>Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare tumor type, and a standard therapy for EP-NEC has not yet been established. The purpose of this research was to explore the overall survival (OS) and therapeutic effects of platinum-etoposide combination therapy in EP-NEC.
This retrospective study was conducted based on the medical records from January 2010 to March 2020. Eligible patients had been pathologically diagnosed with EP-NEC.
Forty-seven patients were included in the study. About 72.3% (n=34) of the patients were diagnosed with metastatic disease at the first diagnosis. The most common primary tumor site was the stomach. The median progression-free survival (PFS) of the patient group, who received the combination of platinum/etoposide, was 5.83 months (95% CI 4.46-7.20), whereas the median OS of the patients, who were found to have metastatic disease at the first diagnosis, was 13.6 months (95% CI 9.01-18.18). There was no difference in PFS and OS between patients with and without liver metastasis.
The outcome of advanced EP-NECs with platinum/etoposide chemotherapy remains poor. Obviously, there is a need for new, more effective treatment options.</abstract><cop>Turkey</cop><pub>KARE Publishing</pub><pmid>35340315</pmid><doi>10.14744/nci.2021.47887</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-0430-6421</orcidid><orcidid>https://orcid.org/0000-0002-5797-0804</orcidid><orcidid>https://orcid.org/0000-0002-5362-0284</orcidid><orcidid>https://orcid.org/0000-0003-0558-9371</orcidid><orcidid>https://orcid.org/0000-0003-4658-1552</orcidid><orcidid>https://orcid.org/0000-0003-2394-3012</orcidid><orcidid>https://orcid.org/0000-0001-8440-3082</orcidid><orcidid>https://orcid.org/0000-0003-4966-3561</orcidid><orcidid>https://orcid.org/0000-0002-4318-2129</orcidid><orcidid>https://orcid.org/0000-0002-8664-5701</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2148-4902 |
| ispartof | Northern Clinics of Istanbul, 2022, Vol.9 (1), p.35-40 |
| issn | 2148-4902 2149-4902 2536-4553 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8889205 |
| source | PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Cancer Care and treatment Chemotherapy Combination therapy Development and progression Etoposide Health aspects Liver Medical records Medical research Medicine, Experimental Metastasis Original - Medical Oncology Patients |
| title | A single center's experience of the extrapulmonary neuroendocrine carcinomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T23%3A44%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20single%20center's%20experience%20of%20the%20extrapulmonary%20neuroendocrine%20carcinomas&rft.jtitle=Northern%20Clinics%20of%20Istanbul&rft.au=Celik,%20Emir&rft.date=2022&rft.volume=9&rft.issue=1&rft.spage=35&rft.epage=40&rft.pages=35-40&rft.issn=2148-4902&rft.eissn=2536-4553&rft_id=info:doi/10.14744/nci.2021.47887&rft_dat=%3Cgale_pubme%3EA789049144%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3095336883&rft_id=info:pmid/35340315&rft_galeid=A789049144&rfr_iscdi=true |